Skip to main content
Clinical Trials/JPRN-UMIN000027821
JPRN-UMIN000027821
Recruiting
Phase 2

Phase II study of allogeneic hematopoietic cell transplantation for children with acute myeloid leukemia in first and second complete remission using fludarabine, cytarabine, melphalan and low-dose total body irradiation as a conditioning regimen (AML-SCT15). - AML-SCT5

Japan Children's Cancer Group (JCCG)0 sites66 target enrollmentJuly 1, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
acute myeloid leukemia (AML)
Sponsor
Japan Children's Cancer Group (JCCG)
Enrollment
66
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Japan Children's Cancer Group (JCCG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Exclusion criteria 1\)Patients who have extramedullary lesions at registry 2\)Patients who have prior radiation therapy 3\)Patients who have prior hematopoietic cell transplantation 4\)Patients who have poorly controlled infectious disease 5\)Patients who have psychiatric disorder 6\)Patients who have coinciding malignancies 7\)Patients who have an episode of hypersensitivity reactions against drugs used in conditioning regimens and/or GVHD prophylaxis 8\)Pregnant women or women who may be pregnant 9\)Patients who are considered as inappropriate for this trial by attending physicians

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
AML-SCT15acute myeloid leukemia (AML)
JPRN-jRCTs051180190YABE Hiromasa66
Completed
Phase 2
Phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and fludarabine as conditioning regimeacute myeloid leukemia(AML) myelodysplastic syndrome(MDS) chronic myelogenous leukemia(CML)
JPRN-UMIN000009766Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital75
Recruiting
Phase 2
Phase II study of allogeneic hematopoietic stem cell transplantation using a preparative regimens consisting of iv Bu + Flu + L-PAM for patients with juvenile myelomonocytic leukemia (JMML)Juvenile myelomonocytic leukemia (JMML)
JPRN-UMIN000005936Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)43
Completed
Phase 2
A phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using intravenous busulfan and cyclophosphamide as conditioning regimen.CML(chronic myelogenous leukemia) AML(acute myeloid leukemia) MDS(myelodysplastic syndrome)
JPRN-UMIN000003648Kanto Study Group for Cell Therapy Nagoya Blood and Marrow Transplantation (NBMT) Group40
Completed
Phase 2
Randomized phase II study of allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and cyclophosphamide as conditioning regimeacute myeloid leukemia(AML) myelodysplastic syndrome(MDS) chronic myelogenous leukemia(CML)
JPRN-UMIN000009762Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital68